Zydus Lifesciences Q1 Net Profit Rises 3.3% YoY to ₹1,466.8 Crore

Disclaimer This is an AI-assisted live blog with updates sourced from multiple news outlets and agencies Disclaimer

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

live

• bselive
• nselive

Volume

Todays L/H

More

×

Zydus Lifesciences Limited announced a 3.3% year-on-year increase in consolidated net profit to ₹1,466.8 crore for the first quarter of FY26, compared to Q1 FY25 (June 2024). Revenue from operations grew by 5.9% to ₹6,573.7 crore.

Key Financial Highlights:

• Research & Development (R&D) investments for the quarter stood at ₹485.6 crore, which is 7.4% of revenues.
• EBITDA margin for the quarter stood at 31.8%.
• Capex (organic) for the quarter was ₹402 crore.

Business-wise Sales Performance (Consolidated):

India Geography:

• Registered revenues of ₹2,374.4 crore, up 6% YoY.

Formulations business:

• Registered revenues of ₹1,519.5 crore, up 8% y-o-y.

Consumer Wellness business:

• Registered revenues of ₹854.9 crore, up 2% YoY.

US formulations business:

• Registered revenues of ₹3,181.7 crore, up 3% YoY and 2% QoQ.

International Markets formulations business:

• Registered revenues of ₹726.5 crore, up 37% YoY.

API business:

• Registered revenues of ₹157.5 crore, up 11% YoY.

Alliances and Others:

• Registered revenues of ₹26.9 crore, down 28% YoY.

The Company will host its post results' earnings call at 4:00 p.m. IST on 12th August, 2025 during which the leadership team will discuss the financial performance and address questions from the participants.